Pliant Therapeutics is developing selective small molecule integrin inhibitors to target the molecular drivers of fibrotic diseases, including idiopathic pulmonary fibrosis. Their approach aims to provide safer and more effective treatment options for patients suffering from these debilitating conditions.
Funding
$287.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Idiopathic pulmonary fibrosis and other fibrotic diseases lack effective treatments, leading to significant morbidity and mortality. Current therapies often have limited efficacy and substantial side effects due to non-specific targeting of the underlying molecular drivers of fibrosis.
Solution
Pliant Therapeutics is developing selective, small-molecule integrin inhibitors designed to address the molecular mechanisms driving fibrotic diseases. Their approach focuses on tissue-specific therapies, with a pipeline that includes clinical-stage programs targeting specific integrins involved in fibrosis. By selectively inhibiting these integrins, Pliant aims to provide safer and more effective treatment options that can halt or reverse the progression of fibrotic diseases with reduced off-target effects. Their lead candidate, Bexotegrast, is an oral small molecule integrin inhibitor in late-stage clinical development for idiopathic pulmonary fibrosis.
Target Audience
The primary target audience includes patients suffering from fibrotic diseases such as idiopathic pulmonary fibrosis, as well as healthcare providers specializing in pulmonology and oncology.
Features
- Selective small molecule integrin inhibitors for targeted therapy
- Tissue-specific approach to minimize off-target effects
- Oral bioavailability for convenient administration
- Clinical-stage programs with ongoing trials
- Focus on key integrins involved in the fibrotic process
- Pipeline includes treatments for idiopathic pulmonary fibrosis, oncology, and muscular dystrophy